Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Ranked against 26 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | $251.9B | 32.8× | 20.9× | 6.9× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.2× | 1,228 |
| GILD | $211.8B | 25.2× | 22.8× | 7.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 787 |
| MRNA | $88.9B | — | — | 45.8× | -39.9% | 55.3% | -145% | -32.6% | -30.5% | — | 279 |
| BIIB | $37.5B | 28.9× | 16.6× | 3.8× | 2.2% | 75.7% | 13.1% | 7.1% | 5.3% | 2.4× | 288 |
| EXEL | $17.2B | 25.0× | 18.5× | 7.4× | 7.0% | 96.4% | 33.7% | 36.2% | 36.2% | -0.5× | 196 |
| HALO | $14.9B | 51.2× | 35.2× | 10.7× | 37.6% | 83.6% | 22.7% | 649% | 14.5% | 4.2× | 187 |
| NBIX | $14.9B | 31.3× | 22.0× | 5.2× | 21.4% | 98.2% | 16.7% | 14.7% | 14.7% | -1.1× | 181 |
| RGEN | $12.0B | 219.3× | 126.0× | 16.2× | 16.4% | 52.3% | 6.6% | 2.3% | 1.8% | -0.3× | 109 |
| TWST | $11.5B | — | — | 30.5× | 20.3% | 50.7% | -20.6% | -16.4% | -16.4% | — | 67 |
| TECH | $11.4B | 62.7× | 31.9× | 9.4× | -0.4% | 65.8% | 15.0% | 8.6% | 8.6% | -0.8× | 115 |
| QGEN | $10.4B | 25.9× | 17.0× | 5.0× | 5.7% | 62.2% | 20.3% | 11.2% | 7.8% | 1.2× | — |
| KRYS | $9.6B | 47.5× | 54.5× | 24.7× | 33.9% | — | 52.6% | 16.8% | 16.8% | -3.0× | 86 |
| IOVA | $4.3B | — | — | 16.4× | 60.6% | 34.3% | -148% | -56.0% | -56.0% | — | 50 |
| ADPT | $4.3B | — | — | 15.3× | 54.8% | 74.2% | -21.5% | -27.2% | -17.0% | — | 52 |
| ADMA | $2.6B | 19.0× | 12.7× | 5.0× | 19.6% | 57.4% | 28.8% | 30.8% | 26.7% | -0.1× | 72 |
| RXRX | $2.5B | — | — | 33.9× | 26.9% | 5.0% | -863% | -57.0% | -56.1% | — | 63 |
| VCEL | $2.2B | 134.1× | 92.8× | 8.0× | 16.5% | 74.4% | 6.0% | 4.7% | 4.7% | -4.4× | 55 |
| BCRX | $2.2B | 7.0× | 6.1× | 2.5× | 94.1% | 97.8% | 30.2% | -221% | -221% | -0.3× | 43 |
| VIR | $2.0B | — | — | 29.0× | -7.6% | 100.0% | -639% | -57.2% | -57.2% | — | 42 |
| NVAX | $1.7B | 4.1× | 3.6× | 1.5× | 64.7% | 93.5% | 39.2% | -345% | 378% | 0.0× | 44 |
| IMCR | $1.6B | — | — | 4.0× | 29.0% | 98.7% | -8.9% | -9.3% | -9.3% | — | 14 |
| AUTL | $405M | — | — | 5.4× | 645% | -27.8% | -381% | -161% | -161% | — | 10 |
| PLX | $210M | — | — | 4.0× | -1.2% | 48.8% | -12.5% | -13.7% | -13.7% | — | 14 |
| CGEN | $188M | 5.2× | 3.0× | 2.6× | 161% | 87.3% | 48.6% | 34.4% | 34.4% | -2.9× | 12 |
| CHRS | $128M | 0.6× | — | 3.0× | 59.8% | 67.2% | — | 275% | 275% | — | 21 |
Peers = companies sharing QGEN's sector (Biological Products, (No Diagnostic Substances)) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $50.22 today, the market must believe free cash flow compounds 6.8%/yr for a decade (off $423.1M on the 3-yr avg basis).
On the basis ($376.1M) the requirement is 8.3%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 6.8% is in line with its 9-yr track record.
Default is 7.9% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.21B shares (market data) · net debt $815.4M
mean 12.6% · volatility σ 38% · implied rate exceeded in 5/9 yrs
Central path = implied 6.8%/yr growth; shaded band = ±1σ (38%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 12% of free cash flow, leaving room to grow it and fund buybacks. Last year: $54.2M dividends + $280.1M buybacks = $334.3M returned on $453.3M FCF.
1 consecutive years of dividend increases.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.09B 100.0% | $1.98B 100.0% | $1.97B 100.0% | $2.14B 100.0% | $2.25B 100.0% | $1.87B 100.0% | $1.53B 100.0% | $1.50B 100.0% | $1.42B 100.0% | $1.34B 100.0% |
| Cost of Revenue | $790.5M 37.8% | $1.01B 51.1% | $731.6M 37.2% | $757.0M 35.3% | $800.8M 35.6% | $637.6M 34.1% | $521.2M 34.1% | $500.9M 33.4% | $495.0M 34.9% | $493.3M 36.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $495.0M 34.9% | $493.3M 36.9% |
| Gross Profit | $1.30B 62.2% | $967.4M 48.9% | $1.23B 62.8% | $1.38B 64.7% | $1.45B 64.4% | $1.23B 65.9% | $1.01B 65.9% | $1.00B 66.6% | $922.6M 65.1% | $844.7M 63.1% |
| Selling, General & Admin | $125.7M 6.0% | $113.4M 5.7% | $119.3M 6.1% | $129.7M 6.1% | $128.1M 5.7% | $111.7M 6.0% | $112.3M 7.4% | $104.6M 7.0% | $102.1M 7.2% | $376.3M 28.1% |
| Total Operating Expenses | $833.6M 39.9% | $869.6M 44.0% | $823.8M 41.9% | $853.1M 39.8% | $820.7M 36.5% | $846.3M 45.2% | $1.03B 67.6% | $734.4M 48.9% | $769.1M 54.3% | $745.8M 55.7% |
| Operating Income | $465.9M 22.3% | $97.7M 4.9% | $409.9M 20.9% | $531.5M 24.8% | $630.1M 28.0% | $386.4M 20.7% | -$26.1M -1.7% | $266.6M 17.8% | $153.4M 10.8% | $98.8M 7.4% |
| Interest Expense | $33.3M 1.6% | $43.8M 2.2% | $53.4M 2.7% | $58.4M 2.7% | $54.5M 2.4% | $71.3M 3.8% | $74.2M 4.9% | $67.3M 4.5% | $49.7M 3.5% | $39.0M 2.9% |
| Interest & Investment Income | $64.3M 3.1% | $68.0M 3.4% | $79.0M 4.0% | $32.8M 1.5% | $9.6M 0.4% | $10.0M 0.5% | $22.1M 1.4% | $20.9M 1.4% | $10.6M 0.8% | $6.8M 0.5% |
| Other Income (Expense), net | $24.4M 1.2% | $23.4M 1.2% | $19.9M 1.0% | -$18.9M -0.9% | -$4.3M -0.2% | $53.0M 2.8% | -$51.6M -3.4% | -$40.8M -2.7% | -$39.0M -2.8% | -$41.9M -3.1% |
| Pretax Income | $490.3M 23.5% | $121.1M 6.1% | $429.8M 21.9% | $512.6M 23.9% | $625.8M 27.8% | $439.5M 23.5% | -$77.8M -5.1% | $225.7M 15.0% | $114.4M 8.1% | $56.9M 4.3% |
| Income Tax Expense | $65.4M 3.1% | $37.6M 1.9% | $88.5M 4.5% | $89.4M 4.2% | $113.2M 5.0% | $80.3M 4.3% | -$36.3M -2.4% | $35.4M 2.4% | $74.0M 5.2% | -$23.4M -1.7% |
| Net Income | $424.9M 20.3% | $83.6M 4.2% | $341.3M 17.4% | $423.2M 19.8% | $512.6M 22.8% | $359.2M 19.2% | -$41.5M -2.7% | $190.4M 12.7% | $40.4M 2.8% | $80.4M 6.0% |
| Per Share | ||||||||||
| EPS (Basic) | $1.96 | $0.38 | $1.50 | $1.86 | $2.25 | $1.57 | -$0.18 | $0.84 | $0.18 | $0.34 |
| EPS (Diluted) | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 | $1.53 | -$0.18 | $0.82 | $0.17 | $0.34 |
| Weighted Avg Shares (Basic) | 217.2M | 222.6M | 228.1M | 227.6M | 228.0M | 228.4M | 226.8M | 226.6M | 228.1M | 234.8M |
| Weighted Avg Shares (Diluted) | 218.9M | 224.7M | 230.6M | 230.1M | 232.0M | 234.2M | 226.8M | 233.5M | 233.0M | 239.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $839.0M covers the $0 due within a year 839005000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (20-F).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~2.0% on $1.65B of debt.
Cash of $839.0M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 14-yr range · 50th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 11% against ROIC 8% — 3% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 66.7× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 33.4 | 34.1 | 34.1 | 35.6 | 35.3 | 37.2 | 51.1 | 37.8 |
| Gross Profit | 66.6 | 65.9 | 65.9 | 64.4 | 64.7 | 62.8 | 48.9 | 62.2 |
| SG&A | 7.0 | 7.4 | 6.0 | 5.7 | 6.1 | 6.1 | 5.7 | 6.0 |
| Operating Income | 17.8 | -1.7 | 20.7 | 28.0 | 24.8 | 20.9 | 4.9 | 22.3 |
| Income Tax | 2.4 | -2.4 | 4.3 | 5.0 | 4.2 | 4.5 | 1.9 | 3.1 |
| Net Income | 12.7 | -2.7 | 19.2 | 22.8 | 19.8 | 17.4 | 4.2 | 20.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on QGEN: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns -0.29pts against its cost of capital — capital is being consumed, not created.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | -0.6% | 7.9% (today's — no rate published for this year) | -8.5pts |
| FY2020 | 7.2% | 7.9% (today's — no rate published for this year) | -0.7pts |
| FY2021 | 11.5% | 4.5% | 7.0pts |
| FY2022 | 8.8% | 7.6% | 1.2pts |
| FY2023 | 6.7% | 7.7% | -1.0pts |
| FY2024 | 1.7% | 8.5% | -6.8pts |
| FY2025 | 7.6% | 7.2% | 0.4pts |
| Now | 7.8% | 7.9% | -0.1pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 63.1% | 7.4% | 6.0% |
| FY2017 | 65.1% | 10.8% | 2.8% |
| FY2018 | 66.6% | 17.8% | 12.7% |
| FY2019 | 65.9% | -1.7% | -2.7% |
| FY2020 | 65.9% | 20.7% | 19.2% |
| FY2021 | 64.4% | 28.0% | 22.8% |
| FY2022 | 64.7% | 24.8% | 19.8% |
| FY2023 | 62.8% | 20.9% | 17.4% |
| FY2024 | 48.9% | 4.9% | 4.2% |
| FY2025 | 62.2% | 22.3% | 20.3% |
Leverage and buybacks account for 3 points of the 11% return on equity in FY2025. The business earns 8% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
$2.7B of goodwill — 56% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer. With goodwill over half the base, the ex-goodwill figure divides by a small remainder and moves sharply — read it as a direction, not a precise rate.
ROIC ex-goodwill is 17.44% against 7.62% reported — the return is earned on a capital base inflated by what was paid for acquisitions, not by the operating business alone.
Converts 2.06x of reported profit into free cash flow over 5 years, with accruals negative.
Reported free cash flow is $453M; after share-based compensation it is $403M. The difference is a real cost that the cash flow statement adds back.
Covers interest 9.8x even after a 30% EBITDA decline.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 14.01x |
| 5% | 13.31x |
| 10% | 12.61x |
| 15% | 11.91x |
| 20% | 11.21x |
| 25% | 10.51x |
| 30% | 9.81x |
| 35% | 9.11x |
| 40% | 8.40x |
| 45% | 7.70x |
| 50% | 7.00x |
| 55% | 6.30x |
| 60% | 5.60x |
Ladder as of 2025-12-31 (20-F); cash from the 2025-12-31 balance sheet; FCF from FY2025.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
The maturity schedule is not part of this verdict — its filing anchor is often older than the balance sheet it sits beside, so a wall inside 24 months may not be visible here.
At $50.34, free cash flow must compound 6.96%/yr for 10 years. It has done 13.42%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | 52.7% | 7.0% |
| FY2021 | 38.2% | 7.0% |
| FY2022 | 30.5% | 7.0% |
| FY2023 | −47.1% | 7.0% |
| FY2024 | 63.5% | 7.0% |
| FY2025 | −10.5% | 7.0% |
The implied rate has been matched or beaten in 4 of the last 6 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | $425M | $425M |
| Share-based comp | $50M | $475M |
| Other non-cash & working capital | $179M | $654M |
| Operating cash flow | $654M | $654M |
| Capex | −$201M | $453M |
| Free cash flow | $453M | $453M |
| FCF after SBC | $403M | $403M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 22.5% | -1.2% | -23.7 points |
| FY2021 | 20.4% | -4.8% | -25.2 points |
| FY2022 | -4.9% | -10.6% | -5.7 points |
| FY2023 | -8.2% | 17.9% | 26.2 points |
| FY2024 | 0.7% | -8.5% | -9.2 points |
| FY2025 | 5.7% | 15.3% | 9.6 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 92.1 days | 119.6 days | 59.4 days | 152.3 days |
| FY2020 | 74.3 days | 166.7 days | 67.6 days | 173.3 days |
| FY2021 | 58.7 days | 149.3 days | 46.1 days | 161.8 days |
| FY2022 | 55.2 days | 172.6 days | 47.6 days | 180.2 days |
| FY2023 | 70.9 days | 198.8 days | 42 days | 227.7 days |
| FY2024 | 64.4 days | 100.8 days | 30.1 days | 135.2 days |
| FY2025 | 70.3 days | 139.4 days | 33.5 days | 176.2 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -7.1 percent |
| FY2020 | -1.7 percent |
| FY2021 | -2.1 percent |
| FY2022 | -4.6 percent |
| FY2023 | -1.9 percent |
| FY2024 | -10.4 percent |
| FY2025 | -3.6 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.